Proprietary AI analyst is now available

InventisBio Valuation Multiples

Discover revenue and EBITDA valuation multiples for InventisBio and similar public comparables like Alembic Pharmaceuticals, AnaptysBio, Hualan Biological Vaccine, Yantai Dongcheng and more.

InventisBio Overview

About InventisBio

InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of innovative targeted drugs with patent protection, covering non-small cell lung cancer, breast cancer, colorectal cancer and other solid tumors, as well as hyperuricemia and metabolic diseases such as gout.


Founded

2013

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $11M
EBITDA: ($44M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

InventisBio Financials

InventisBio reported last 12-month revenue of $11M and negative EBITDA of ($44M).

In the same LTM period, InventisBio generated $10M in gross profit, ($44M) in EBITDA losses, and had net loss of ($42M).

Revenue (LTM)


InventisBio P&L

In the most recent fiscal year, InventisBio reported revenue of $6M and EBITDA of ($44M).

InventisBio is unprofitable as of last fiscal year, with gross margin of 87%, EBITDA margin of (808%), and net margin of (832%).

See analyst estimates for InventisBio
LTMLast FY202320242025202620272028
Revenue$11M$6M$27M$25M$6M
Gross Profit$10M$5M$27M$24M$5M
Gross Margin90%87%100%98%87%
EBITDA($44M)($44M)($39M)($33M)($44M)
EBITDA Margin(408%)(808%)(143%)(131%)(808%)
EBIT Margin(382%)(832%)(170%)(156%)(885%)
Net Profit($42M)($46M)($42M)($35M)($47M)
Net Margin(382%)(832%)(153%)(142%)(850%)

Financial data powered by Morningstar, Inc.

InventisBio Stock Performance

InventisBio has current market cap of $2B, and enterprise value of $1B.

Market Cap Evolution


InventisBio's stock price is $2.61.

InventisBio share price decreased by 9.1% in the last 30 days, and by 45.1% in the last year.

InventisBio has an EPS (earnings per share) of $-0.08.

See more trading valuation data for InventisBio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$2B-0.2%-9.1%-6.3%-45.1%$-0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

InventisBio Valuation Multiples

InventisBio trades at 120.5x EV/Revenue multiple, and (29.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for InventisBio

EV / Revenue (LTM)


InventisBio Financial Valuation Multiples

As of June 5, 2026, InventisBio has market cap of $2B and EV of $1B.

InventisBio has a P/E ratio of (36.4x).

LTMLast FY202320242025202620272028
EV/Revenue120.5x238.1x47.9x52.6x238.1x
EV/EBITDA(29.6x)(29.5x)(33.4x)(40.2x)(29.5x)
EV/EBIT(31.6x)(28.6x)(28.2x)(33.7x)(26.9x)
EV/Gross Profit133.3xn/m47.9x53.9xn/m
P/E(36.4x)(33.0x)(36.0x)(42.6x)(32.3x)
EV/FCF-(54.7x)(28.3x)(35.6x)(54.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified InventisBio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

InventisBio Margins & Growth Rates

InventisBio grew revenue by 232% but EBITDA decreased by 8% in the last fiscal year.

In the most recent fiscal year, InventisBio reported gross margin of 87%, EBITDA margin of (808%), and net margin of (832%).

See estimated margins and future growth rates for InventisBio

InventisBio Margins

Last FY202420252026202720282029
Gross Margin87%98%87%92%
EBITDA Margin(808%)(131%)(808%)(224%)
EBIT Margin(832%)(156%)(885%)(196%)
Net Margin(832%)(142%)(850%)(196%)
FCF Margin(435%)(148%)(435%)-

InventisBio Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth232%(9%)(78%)232%
Gross Profit Growth252%(11%)(80%)252%
EBITDA Growth(8%)(17%)37%(8%)
EBIT Growth(22%)(16%)25%(27%)
Net Profit Growth(22%)(15%)32%(23%)
FCF Growth-(21%)(35%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

InventisBio Operational KPIs

InventisBio's Rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

InventisBio's Rule of X is 355% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for InventisBio
LTMLast FY202320242025202620272028
Rule of 40(186%)7%---
Bessemer Rule of X146%355%---
S&M Expenses to Revenue6%0%--0%
G&A Expenses to Revenue59%118%23%20%78%
R&D Expenses to Revenue420%874%239%228%874%
Opex to Revenue-972%270%254%972%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

InventisBio Competitors

InventisBio competitors include Alembic Pharmaceuticals, AnaptysBio, Hualan Biological Vaccine, Yantai Dongcheng, ArriVent BioPharma, Vir Biotechnology, MBX Biosciences, Ab&B Bio-Tech, SOTHEMA and Bora Pharmaceuticals.

Most InventisBio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Alembic Pharmaceuticals2.4x2.1x14.7x13.6x
AnaptysBio5.2x6.6x17.8x18.9x
Hualan Biological Vaccine6.8x6.4x24.5x26.0x
Yantai Dongcheng3.7x3.6x17.2x16.3x
ArriVent BioPharma--(6.8x)(6.7x)
Vir Biotechnology16.9x10.7x(2.6x)(2.9x)
MBX Biosciences--(10.6x)(8.8x)
Ab&B Bio-Tech41.5x-(59.3x)-

This data is available for Pro users. Sign up to see all InventisBio competitors and their valuation data.

Start Free Trial

InventisBio VC Funding History

Before going public, InventisBio raised $247M in total equity funding, across 4 rounds.


InventisBio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-20Series DGL Ventures LLC$147M-InventisBio is a Shanghai-based clinical-stage biotech company focused on developing first-in-class and best-in-class innovative small molecule drugs for oncology and metabolic diseases, addressing unmet medical needs. The company has built a pipeline including D-0502 (selective estrogen receptor degrader for hormone receptor-positive breast cancer), D-0120 (for gout), and BPI-D0316 (third-generation EGFR-T790M inhibitor for non-small cell lung cancer in registration trials), with multiple candidates in mid-to-late stage clinical development and ongoing registration trials. On September 27, 2020, InventisBio closed a $147 million Series D funding round led by Hillhouse affiliate GL Ventures, with participation from new investors Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital, and returning investors including Lilly Asia Ventures, OrbiMed Asia, Pudong Innotek, Advantech Capital, and CMB International. This brought total funding to approximately $247 million, following a $70 million Series C in 2019, $19 million Series B in 2017, and earlier rounds. Proceeds from the Series D will advance Phase II clinical trials for D-0502 and D-0120 in China and the US, support global clinical development of additional pipeline candidates, expand the product pipeline, and grow the team. The round underscores investor confidence in InventisBio's integrated R&D platform, experienced leadership with over 20 years in drug discovery, and potential as a global pharmaceutical player.
Mar-19Series CAdvantech Capital; CMB International Capital Corporation; Lilly Asia Ventures; OrbiMed$70M-InventisBio Inc., a Shanghai-based clinical-stage biotech company founded in 2013, focuses on discovering and developing novel small-molecule therapeutics for cancer (breast cancer, lung cancer, non-small cell lung cancer) and metabolic diseases like gout and hyperuricemia. The company closed a $70 million USD Series C financing in January 2019, co-led by Advantech Capital and CMB International Capital Corporation (CMBI), with participation from Pudong Innotek and existing investors Lilly Asia Ventures (LAV) and OrbiMed Asia. This followed a Series B round of $19 million in 2017 from LAV and OrbiMed, and a Series A of $11 million in 2016 with Sinopharm Capital. The Series C proceeds were intended to accelerate three clinical-stage drug candidates into Phase 2 trials and advance first-in-class candidates to clinical stages, emphasizing global multi-center trials for unmet needs. At the time, InventisBio had licensed its third-generation EGFR-T790M inhibitor D-0316's China rights to Betta Pharma for co-development in Phase 2 for NSCLC. Subsequently, InventisBio raised a Series D round of 1 billion yuan ($147 million) in September 2020 led by Hillhouse Capital, with new investors including Qiming Venture Partners, Matrix Partners China, Janchor Partners, AIHC Capital, DYEE Capital, and E Fund. The funds supported Phase II trials in China and the US, global clinical development, and team expansion. In July 2022, InventisBio listed on the Shanghai STAR Market at CNY 18.12 per share, achieving a market cap of CNY 10.419 billion, marking Qiming's investment success.
May-17Series BLilly Asia Ventures; OrbiMed$19M-InventisBio is a Shanghai-based biotechnology company founded in 2013 by Dr. Yaolin Wang, dedicated to discovering and developing novel medicines for oncology and metabolic diseases such as breast cancer, lung cancer, and gout. The company's founding team includes scientists with prior experience at pharmaceutical companies including Merck and Schering-Plough. At the time of the Series B round in May 2017, InventisBio had four early-stage drug candidates, with three expected to enter phase 1 clinical trials in the United States and China by the end of 2017. The company was actively developing drugs designed to be combined with immuno-oncology targeted therapies such as PD-1 antibodies for various cancer indications. InventisBio raised $19 million in Series B financing on May 30, 2017, led by OrbiMed Asia Partners and joined by returning investor Lilly Asia Ventures. This round followed a $11 million Series A in 2016 co-led by Lilly Asia Ventures and SinoPharm Capital, and a seed round in 2015 led by Beautiful Mind Investment Management. The Series B funding was earmarked to accelerate product development through phase 1 clinical trials and support future global market expansion. By the time of this round, InventisBio had accumulated $30 million in total funding.
Jan-16Series ALilly Asia Ventures; Sinopharm Capital; Spinnotec$11M-InventisBio is a Shanghai-based clinical-stage biotech company founded in 2013 by Dr. Yaolin Wang, focused on developing small molecule drugs and immunotherapies for oncology and metabolic diseases including breast cancer, lung cancer, and gout. The company received Series A financing of $11 million in 2016 led by Lilly Asia Ventures in partnership with state-owned Sinopharm Capital. This followed angel investment from Beautiful Mind Capital. Subsequent rounds included a $19 million Series B in 2017 led by OrbiMed Asia with LAV participation, a $70 million Series C in January 2019 led by LAV with OrbiMed, CMB International, Pudong Innotek, and AdvanTech Capital, and a 1 billion yuan ($147 million) Series D in September 2020 led by Hillhouse Capital with Qiming Venture Partners, Matrix Partners China, Janchor Partners, AIHC Capital, DYEE Capital, and E Fund. Funds from later rounds supported advancement of clinical candidates to phase 2 trials, global development, and team expansion. In December 2018, InventisBio licensed China rights for its third-generation EGFR inhibitor D-0316 to Betta Pharma for co-development in phase 2 for non-small cell lung cancer.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About InventisBio

When was InventisBio founded?InventisBio was founded in 2013.
Where is InventisBio headquartered?InventisBio is headquartered in China.
Is InventisBio publicly listed?Yes, InventisBio is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of InventisBio?InventisBio trades under 688382 ticker.
When did InventisBio go public?InventisBio went public in 2022.
Who are competitors of InventisBio?InventisBio main competitors include Alembic Pharmaceuticals, AnaptysBio, Hualan Biological Vaccine, Yantai Dongcheng, ArriVent BioPharma, Vir Biotechnology, MBX Biosciences, Ab&B Bio-Tech, SOTHEMA, Bora Pharmaceuticals.
What is the current market cap of InventisBio?InventisBio's current market cap is $2B.
What is the current revenue of InventisBio?InventisBio's last 12 months revenue is $11M.
What is the current revenue growth of InventisBio?InventisBio revenue growth (NTM/LTM) is 221%.
What is the current EV/Revenue multiple of InventisBio?Current revenue multiple of InventisBio is 120.5x.
Is InventisBio profitable?No, InventisBio is not profitable.
What is the current EBITDA of InventisBio?InventisBio has negative EBITDA and is not profitable.
What is InventisBio's EBITDA margin?InventisBio's last 12 months EBITDA margin is (408%).
What is the current EV/EBITDA multiple of InventisBio?Current EBITDA multiple of InventisBio is (29.6x).
How many companies InventisBio has acquired to date?InventisBio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies InventisBio has invested to date?InventisBio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to InventisBio

Lists including InventisBio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial